Sanofi CEO Paul Hudson’s recently-announced decision to discontinue research and development and new launches in the diabetes/cardiovascular arena offers a window into how US lawmakers’ failure to reform pharmacy benefit management is playing out for at least one company.
Hudson recently joined Sanofi from Novartis and his plan to break with the past and walk away from diabetes research was announced as part of his new vision for the company during a presentation to investors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?